BRIEF—China's Hansoh files for approval of generic Kyprolis

China's Hansoh Pharma has filed an Abbreviated New Drug Application (ANDA) in China for the approval of a generic version of Amgen's Kyprolis (carfilzomib).

The original drug was cleared for marketing in the country to treat multiple myeloma in July 2021 under a partnership between Amgen and BeiGene.

The Kyprolis patent is set to expire in China in 2025.

If approved, Hansoh would be the first Chinese company supplying a carfilzomib generic. There are five other Chinese companies working on the generic version, including CSPC Pharmaceutical and Chia Tai‑Tianqing Pharmaceutical.